USClinicalTrials.govClinical trialPhase 2Recruiting
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
Official record
- Identifier
NCT07069712- Recruiting locations
countries
United StatesCanadaChinaGeorgiaItalyJapanPolandSpainTaiwanTurkey (Türkiye)United Kingdom- Interventions studied
- Sonesitatug VedotinRilvegostomigTrastuzumab Deruxtecan (T-DXd)Capecitabine5-Fluorouracil (5-FU)FLOT ChemotherapyCalcium folinate
- Lead sponsor
- AstraZeneca
- Target enrolment
- 100 participants
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Status
- Recruiting
- First posted
- Jul 17, 2025
- Last updated on the registry
- Sep 24, 2026
- Age
- 18 Years
- Sex
- ALL
- Study contact
- The official record lists a study contact. Contact details are published there and are intentionally not copied to this page.
- Eligibility criteria
Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.
Inclusion Criteria: * Histologically documented gastric, GEJ, or esophageal adenocarcinoma with resectable disease * Participants who are CLDN18.2-positive in Sub-study 1 or HER2-positive in Sub-study 2; no specific requirements for Sub-study 3 * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Adequate organ and bone marrow function * Body weight \> 35 kg Exclusion Criteria: * Participants had any prior anti-cancer treatment or surgery for the current gastric, GEJ, or esophageal cancer. * Active or prior documented autoimmune or inflammatory disorders requiring systemic treatment with steroids or other immunosuppressive treatment * Central nervous system (CNS) pathology * Uncontrolled infections * Participants with history of (non-infectious) interstitial lung disease (ILD)/pneumonitis, current ILD/pneumonitis, or suspected ILD/pneumonitis * History of another primary malignancy * Participants with any known or suspicious distant metastasis * Uncontrolled hepatitis B and/or chronic or active hepatitis B * Current or prior use of immunosuppressive medication within 14 days before the first dose of study intervention
- Indexed under
- Gastric Cancer